Peptides for Longevity: BPC-157, TB-500, Sermorelin, and the Evidence Gap That Matters
Peptide therapies occupy a unique and uncomfortable position in longevity medicine: widely used by longevity-oriented physicians and biohackers, producing compelling anecdotal results and interesting preclinical data, but almost entirely lacking the randomized controlled trial evidence in humans that would allow confident clinical recommendations. This is an honest assessment of what the evidence shows - and does not show.
- Peptides used in longevity medicine are short chains of amino acids - typically 5 to 50 amino acids - that mimic or modulate endogenous signaling molecules. They are generally administered by subcutaneous injection (for most therapeutic peptides) or orally (for some research peptides) and have short half-lives requiring frequent dosing.
- BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from human gastric juice that demonstrates potent tissue repair, anti-inflammatory, and neuroprotective effects in animal models - including accelerated healing of tendons, ligaments, muscle, bone, and gut tissue. Human RCT data is essentially absent as of 2025.
- GH secretagogues - peptides that stimulate endogenous growth hormone release (sermorelin, ipamorelin, CJC-1295, tesamorelin) - increase GH pulsatility and IGF-1 levels in ways that partially reverse somatopause. They are increasingly used in longevity medicine as a safer alternative to exogenous GH administration, preserving the physiological pulsatile pattern of GH secretion.
- The regulatory status of most longevity peptides is ambiguous and rapidly evolving. BPC-157 and TB-500 are not FDA-approved for human use but are widely available through compounding pharmacies and research chemical suppliers. The FDA has been increasing enforcement actions against compounding pharmacies dispensing unapproved peptides. Quality control and purity of non-pharmaceutical-grade peptides is a legitimate safety concern.
- The honest evidence assessment: GH secretagogues have the most developed human evidence base among longevity peptides, with published studies showing IGF-1 elevation, body composition improvement, and sleep quality improvement. BPC-157 has extraordinary preclinical data but essentially no human RCT evidence. TB-500 (thymosin beta-4) has some human studies in wound healing. All longevity peptide use beyond approved indications should be considered experimental.
Peptide therapies represent one of the most rapidly evolving and evidence-poor domains in longevity medicine. The interest is understandable: endogenous peptides are extraordinarily important signaling molecules - insulin, GLP-1, GH-releasing hormone, and hundreds of others coordinate metabolism, growth, repair, and immune function across the entire body. Pharmaceutical-grade versions of naturally occurring peptides (insulin, semaglutide, tesamorelin) have transformed medicine. The logical extension - that additional peptides with interesting preclinical biology could provide clinical benefit - is plausible. But plausibility is not evidence, and the evidence gap in longevity peptides is significant.1
BPC-157: The Most Discussed Research Peptide
BPC-157 is a synthetic peptide consisting of 15 amino acids, derived from a sequence found in human gastric juice protein. It was first characterized by Predrag Sikiric at the University of Zagreb beginning in the 1990s. The preclinical literature on BPC-157 is extensive and consistently positive: it accelerates healing of tendons, ligaments, muscle, bone, and gut tissue in rat and mouse models; demonstrates neuroprotective effects after traumatic brain injury and spinal cord damage; reverses organ damage from toxins including NSAIDs and alcohol; has anti-inflammatory effects via nitric oxide and growth factor signaling; and produces anxiolytic and antidepressant effects in animal behavioral models.2
The human evidence is essentially absent. As of 2025, no published randomized controlled trial has evaluated BPC-157 in humans for any indication. The single human study that is widely cited - a Sikiric et al. pilot study in inflammatory bowel disease - was small, uncontrolled, and not published in a peer-reviewed journal. The preclinical data is compelling enough that human trials are warranted, but compelling preclinical data has repeatedly failed to translate to human clinical benefit in other domains (see: antioxidant megadosing). BPC-157 is used experimentally in longevity medicine with anecdotal reports of improved recovery from musculoskeletal injuries. Its use should be considered experimental pending human RCT data.
GH Secretagogues: The Most Developed Human Evidence
Growth hormone secretagogues (GHS) are peptides that stimulate GH release from the pituitary via binding to the ghrelin receptor (GHSR) or GHRH receptor. The major classes include: GHRH analogs (sermorelin, CJC-1295, tesamorelin) which bind the GHRH receptor and stimulate physiological pulsatile GH release; and GHRPs (ipamorelin, hexarelin, GHRP-2, GHRP-6) which bind the ghrelin receptor (GHSR-1a) and also stimulate GH release, sometimes with appetite stimulation as a side effect.3
Tesamorelin is the most clinically established GH secretagogue - it is FDA-approved for HIV-associated lipodystrophy and has published RCT data in this population showing improved body composition, reduced visceral fat, and improved lipid profiles. Sermorelin was previously FDA-approved as a diagnostic agent and has been used off-label in longevity medicine. Ipamorelin and CJC-1295 are widely used in longevity practice based on their favorable GH-stimulating profiles and lower side effect burden compared to older GHRPs, but lack the robust human clinical data of tesamorelin.
TB-500 (Thymosin Beta-4)
Thymosin beta-4 (TB4) is a naturally occurring 43-amino acid peptide involved in actin polymerization, cell migration, and tissue repair. TB-500 is a synthetic fragment of TB4 that is claimed to retain its tissue-healing properties. TB4 itself has been studied in human wound healing trials with modest positive results. The synthetic TB-500 fragment has a less developed human evidence base. Both compounds are of significant interest as potential muscle and tendon repair agents, but the human clinical data is insufficient to draw confident conclusions about efficacy or optimal dosing in the longevity context.4
The Quality and Regulatory Reality
The regulatory status of most longevity peptides creates a quality control problem that deserves explicit acknowledgment. Peptides sourced through compounding pharmacies or research chemical suppliers are not subject to the manufacturing standards required of FDA-approved pharmaceuticals. Independent testing of commercially available peptide products has found significant variation in actual peptide content and purity. This means the risks of peptide use extend beyond the theoretical risks of the compounds themselves to include risks from impurities and inaccurate dosing.5
The excitement surrounding peptide therapies in longevity circles is understandable - the preclinical data for some compounds, particularly BPC-157, is genuinely striking. But the history of longevity science is littered with compounds that demonstrated extraordinary effects in cell culture and animal models and failed to produce clinical benefit in humans. Antioxidants, resveratrol, and dozens of other compounds followed this trajectory. The appropriate response to compelling preclinical data is well-designed human trials, not widespread experimental use in the absence of such trials. Anyone using peptide therapies outside of approved clinical indications should understand they are participating in an uncontrolled experiment without clear safety or efficacy data.
References
- 1Marx V. "Rethinking the peptide as a drug." Nature Methods. 2005;2(3):167-171. [PubMed]
- 2Sikiric P, et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Current Neuropharmacology. 2016;14(8):857-865. [PubMed]
- 3Sigalos JT, Pastuszak AW. "The safety and efficacy of growth hormone secretagogues." Sexual Medicine Reviews. 2018;6(1):45-53. [PubMed]
- 4Goldstein AL, et al. "Thymosin beta4: a multi-functional regenerative peptide." Annals of the New York Academy of Sciences. 2012;1270:1-8. [PubMed]
- 5Tucker GT. "Pharmacological assessment of the compounding of drugs: setting standards." Expert Opinion on Drug Safety. 2016;15(9):1193-1197. [PubMed]